טוען...
Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease
BACKGROUND: Iron isomaltoside 1000 is a novel injectable iron compound which offers potential advantages in the treatment of subjects with iron-deficiency anemia. We studied the pharmacokinetics (PK) of this novel compound in subjects with mild-to-moderate inflammatory bowel disease (IBD). METHODS:...
שמור ב:
| Main Authors: | , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2012
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3299547/ https://ncbi.nlm.nih.gov/pubmed/22419860 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S30015 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|